ECX
ECARX Holdings, Inc.
There isn't enough reported data to score ECX yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
ECX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ECX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ECX PE Valuation
ECX has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
ECX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ECX's earnings to grow and its profitability to improve, with its revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ECX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.61 | — |
| Q4 2025 | -$0.20 | +$0.22 |
| Q4 2024 | -$0.42 | $0.00 |
| Q4 2023 | -$0.42 | +$0.77 |
| Q4 2022 | -$1.19 | +$3.39 |
ECX has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
ECX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $524.6M | +3.8% |
| Q2 2025 | $323.3M | -1.9% |
| Q4 2024 | $505.1M | -28% |
| Q4 2023 | $700.3M | +31% |
| Q4 2022 | $533.8M | +320% |
ECX's revenue is growing: $525M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 2% | +22 points |
| Q2 2025 | -20% | +21 points |
| Q4 2024 | -12% | +23 points |
| Q2 2024 | -22% | +13 points |
| Q4 2023 | -20% | +18 points |
| Q4 2022 | -41% | -3.7 points |
| Q4 2021 | -35% | N/A |
| Q3 2021 | -35% | N/A |
ECX's operating margin was 2% last quarter, up 22 points from the same quarter a year ago, near the top of its range since 2021.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over ECX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
ECX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$20.1M | -$9.3M |
| Q2 2025 | -$86.5M | -$15.5M |
| Q4 2024 | -$10.8M | +$185.1M |
| Q4 2023 | -$195.9M | -$115.9M |
| Q4 2022 | -$80.1M | -$80M |
ECX has burned cash in almost every quarter: −$188M over the past year, against −$276M the year before.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
ECX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.4M shares |
| 1 year | +0.4% | +1.3M shares |
ECX has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
ECX Net Leverage
ECX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ECX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 28.4 | Neutral |
ECX's weekly RSI is 38 (neutral) and its Stochastic is 28 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ECX PE vs Consumer Cyclical Sector
ECX has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
ECX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.88 | 6.8% below |
| 20 week MA | $1.00 | 18% below |
| 50 week MA | $1.25 | 34% below |
| 100 week MA | $1.55 | 47% below |
| 200 week MA | $2.47 | 67% below |
ECX is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
ECX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.70 | $9.71 | +0.1% |
| 2022 | $9.71 | $8.23 | -15% |
| 2023 | $8.23 | $3.16 | -62% |
| 2024 | $3.16 | $1.89 | -40% |
| 2025 | $1.89 | $1.55 | -18% |
| 2026 YTD | $1.55 | $0.82 | -47% |
ECX has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.